Skip to main content
. 2017 Mar 7;8:240. doi: 10.3389/fimmu.2017.00240

Figure 5.

Figure 5

Treatment with AS101 decreases TNFα protein levels and glomerular caspase-3 activity in crescentic glomerulonephritis. Treatment protocol was as described in Figure 2. Serum TNFα (A) and glomerular caspase-3 activity (B) were evaluated 2 weeks after αGBM administration (N − 3/group). #p < 0.01 increase vs. control; **p < 0.01 decrease vs. αGBM. The one-way ANOVA was used. Immunohistochemistry was performed on kidney sections for detection of fibronectin (FN) on week 2 (C). FN expansion was evaluated on weeks 1, 2, 3, and 4 and was scored in 100 glomeruli/sample as follows: grade 0 no staining; grade 1 staining occupying up to 25% of glomerular surface area; grade 2 staining occupying 25–50% of glomerular surface area; grade 3 staining occupying more than 50% of glomerular surface area (D). Data are presented as mean ± SE of five rats/group for each time point. #p < 0.01 increase vs. control; *p < 0.01 decrease vs. αGBM. *p < 0.05 decrease vs. αGBM. The two-way ANOVA was used.